Citizens Jmp Has Lowered Expectations for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its price target dropped by research analysts at Citizens Jmp from $825.00 to $700.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp’s target price would indicate a potential upside of 65.88% from the stock’s previous close.

A number of other research analysts have also recently commented on the stock. Piper Sandler reduced their price target on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a research report on Thursday. UBS Group set a $440.00 target price on shares of Axon Enterprise in a report on Thursday. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Citigroup restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Finally, Robert W. Baird set a $800.00 price target on Axon Enterprise in a research note on Wednesday, February 25th. Sixteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and a consensus price target of $722.38.

Axon Enterprise Price Performance

Shares of AXON stock traded up $36.13 during trading on Thursday, hitting $421.99. The company had a trading volume of 1,579,299 shares, compared to its average volume of 1,049,641. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. The stock’s 50-day moving average is $452.24 and its two-hundred day moving average is $529.24. The stock has a market capitalization of $34.00 billion, a price-to-earnings ratio of 278.40, a price-to-earnings-growth ratio of 8.12 and a beta of 1.44. Axon Enterprise has a 52 week low of $339.01 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.55. The company had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. Axon Enterprise’s revenue for the quarter was up 38.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.08 earnings per share. As a group, analysts predict that Axon Enterprise will post 1.41 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 157 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00. Following the completion of the transaction, the director owned 1,159 shares of the company’s stock, valued at approximately $567,910. This trade represents a 11.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at $29,740,135.88. This represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 13,855 shares of company stock valued at $7,109,828. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. NEOS Investment Management LLC increased its holdings in Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after buying an additional 11,482 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Axon Enterprise by 3.3% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after purchasing an additional 5,953 shares during the period. Legal & General Group Plc grew its stake in shares of Axon Enterprise by 3.1% during the 3rd quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company’s stock valued at $302,208,000 after purchasing an additional 12,736 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Axon Enterprise by 93.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock valued at $13,270,000 after purchasing an additional 11,262 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue beat and strong top-line growth — Axon reported $807M in Q1 revenue (up ~34% YoY), with software & services up 35% and management raised full‑year revenue growth to 30–32% while reaffirming margins and strong cash‑flow targets. Axon reports Q1 2026 revenue of $807 million
• Positive Sentiment: Explosive AI product adoption — management said AI product revenue was up ~700% and counter‑drone revenue rose >300%, driving the guidance raise and investor enthusiasm about recurring ARR and higher‑margin software. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analysts reiterate conviction — multiple firms (William Blair, Needham) maintained Buy ratings and bullish targets (Needham $600 PT), supporting upside expectations. Axon Earns Buy Rating on Robust ARR Growth Axon Maintained at Buy as Strong Growth Outlook Supports Unchanged $600 Price Target
• Neutral Sentiment: Investor resources — transcripts, estimate comparisons and previews are circulating to guide thesis and model updates ahead of analyst revisions. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Mixed earnings signals — while revenue beat, non‑GAAP EPS was marginally mixed versus some estimates (tiny beat vs some consensus, small miss vs others), which capped upside for some traders. Compared to Estimates, Axon Q1 Earnings
• Negative Sentiment: Analyst target tweak & valuation pressure — Piper Sandler trimmed its price target slightly (still Overweight), and recent YTD share weakness / high P/E leave sensitivity to execution and multiple compression. Piper Sandler price target update

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.